While a small trend of improvement appears to be emerging, longer-term data collection is required to ensure sustained patient benefits.
← all excerpts
Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
1
—
—